Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Management of Medication Toxicity or Intolerance
Last Updated: April 16, 2019; Last Reviewed: April 16, 2019
|Adverse Effects||Associated ARVs||Onset/Clinical Manifestations||Estimated Frequency||Risk Factors||Prevention/Monitoring||Management|
DRV causes crystalluria, but it is not associated with nephrolithiasis.
||ATV-related nephrolithiasis occurs in <10% of patients.||In adults, elevated urine pH (>5.7)
The risk factors in children are unknown.
||Provide adequate hydration and pain control. Consider using another ARV in place of ATV.|
||Risk May Increase in Children with the Following Characteristics:
||Monitor urine protein, urine glucose and serum creatinine at 3-month to 6-month intervals. For patients taking TDF, some Panel members routinely monitor serum phosphate levels.
Measure serum phosphate if the patient experiences persistent proteinuria or glucosuria, or has symptoms of bone pain, muscle pain, or weakness.
Because toxicity risk increases with the duration of TDF treatment, do not decrease the frequency of monitoring over time.
|If TDF is the likely cause, consider using an alternative ARV drug. TAF has significantly less toxicity than TDF.|
|Elevation in Serum Creatinine||DTG, COBI, RPV||Onset:
Need to distinguish between a true change in eGFR and other causes. A true change may be associated with other medical conditions, the continuing rise of serum creatinine levels over time, and albuminuria.
|N/A||Monitor serum creatinine. Assess for renal dysfunction if serum creatinine increases by >0.4 mg/dL or if increases continue over time.||No need to change therapy.
Reassure the patient about the benign nature of the laboratory abnormality.
|Key to Acronyms: ARV = antiretroviral; ATV = atazanavir; COBI = cobicistat; dL = deciliter; DRV = darunavir; DTG = dolutegravir; eGFR = estimated glomerular filtration rate; LPV/r = lopinavir/ritonavir; PI = protease inhibitor; RPV = rilpivirine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate|
- Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr Infect Dis J. 2009;28(7):619-625. Available at http://www.ncbi.nlm.nih.gov/pubmed/19561425.
- Judd A, Boyd KL, Stohr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS. 2010;24(4):525-534. Available at http://www.ncbi.nlm.nih.gov/pubmed/20139752.
- Nachman SA, Chernoff M, Gona P, et al. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. Arch Pediatr Adolesc Med. 2009;163(2):164-171. Available at http://www.ncbi.nlm.nih.gov/pubmed/19188649.
- Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. Pediatr Infect Dis J. 2009;28(3):204-209. Available at http://www.ncbi.nlm.nih.gov/pubmed/19209091.
- Soler-Palacin P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS. 2011;25(2):171-176. Available at http://www.ncbi.nlm.nih.gov/pubmed/21076275.
- van Rossum AM, Dieleman JP, Fraaij PL, et al. Indinavir-associated asymptomatic nephrolithiasis and renal cortex atrophy in two HIV-1 infected children. AIDS. 2001;15(13):1745-1747. Available at http://www.ncbi.nlm.nih.gov/pubmed/11546957.
- van Rossum AM, Dieleman JP, Fraaij PL, et al. Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir. Pediatrics. 2002;110(2 Pt 1):e19. Available at http://www.ncbi.nlm.nih.gov/pubmed/12165618.
- Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kid Dis. 2011;57(5):773-780. Available at http://www.ncbi.nlm.nih.gov/pubmed/21435764.
- Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496-505. Available at http://www.ncbi.nlm.nih.gov/pubmed/20673002.
- Vigano A, Bedogni G, Manfredini V, et al. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. Clin Drug Investig. 2011;31(6):407-415. Available at http://www.ncbi.nlm.nih.gov/pubmed/21528939.
- Fraaij PL, Verweel G, van Rossum AM, Hartwig NG, Burger DM, de Groot R. Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment. Infection. 2007;35(3):186-189. Available at http://www.ncbi.nlm.nih.gov/pubmed/17565462.
- Purswani M, Patel K, Kopp JB, et al. Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J. 2013;32(5):495-500. Available at http://www.ncbi.nlm.nih.gov/pubmed/23249917.
- Nishijima T, Hamada Y, Watanabe K, et al. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients. PLoS One. 2013;8(10):e77268. Available at http://www.ncbi.nlm.nih.gov/pubmed/24130871.
- de Lastours V, Ferrari Rafael De Silva E, Daudon M, et al. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother. 2013;68(8):1850-1856. Available at http://www.ncbi.nlm.nih.gov/pubmed/23599359.
- German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61(1):32-40. Available at http://www.ncbi.nlm.nih.gov/pubmed/22732469.
- Yombi JC, Pozniak A, Boffito M, et al. Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS. 2014;28(5):621-632. Available at http://www.ncbi.nlm.nih.gov/pubmed/24983540.
- Lim Y, Lyall H, Foster C. Tenofovir-associated nephrotoxicity in children with perinatally-acquired HIV infection: a single-centre cohort study. Clin Drug Investig. 2015;35(5):327-333. Available at http://www.ncbi.nlm.nih.gov/pubmed/25861908.
- Samarawickrama A, Cai M, Smith ER, et al. Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria. HIV Med. 2012;13(9):526-532. Available at http://www.ncbi.nlm.nih.gov/pubmed/22413854.
- Marcelin JR, Berg ML, Tan EM, Amer H, Cummins NW, Rizza SA. Is abnormal urine protein/osmolality ratio associated with abnormal renal function in patients receiving tenofovir disoproxil fumarate? PLoS One. 2016;11(2):e0149562. Available at https://www.ncbi.nlm.nih.gov/pubmed/26872144.
- Lin KY, Liao SH, Liu WC, et al. Cholelithiasis and nephrolithiasis in HIV-positive patients in the era of combination antiretroviral therapy. PLoS One. 2015;10(9):e0137660. Available at https://www.ncbi.nlm.nih.gov/pubmed/26360703.
- Bunupuradah T, Phupitakphol T, Sophonphan J, et al. Prevalence of persistent renal dysfunction in perinatally HIV-infected Thai adolescents. Pediatr Infect Dis J. 2017. Available at https://www.ncbi.nlm.nih.gov/pubmed/28719505.
- Purswani MU, Patel K, Winkler CA, et al. Brief Report: APOL1 Renal risk variants are associated with chronic kidney disease in children and youth with perinatal HIV infection. J Acquir Immune Defic Syndr. 2016;73(1):63-68. Available at https://www.ncbi.nlm.nih.gov/pubmed/27035887.
- Soares DS, Cavalcante MG, Ribeiro SM, et al. Acute kidney injury in HIV-infected children: comparison of patients according to the use of highly active antiretroviral therapy. J Pediatr (Rio J). 2016;92(6):631-637. Available at https://www.ncbi.nlm.nih.gov/pubmed/27542916.
- Melvin AJ, Warshaw M, Compagnucci A, et al. Hepatic, renal, hematologic, and inflammatory markers in HIV-infected children on long-term suppressive antiretroviral therapy. J Pediatric Infect Dis Soc. 2017;6(3):e109-e115. Available at https://www.ncbi.nlm.nih.gov/pubmed/28903520.
- Unsal AB, Mattingly AS, Jones SE, et al. Effect of Antiretroviral therapy on bone and renal health in young adults with HIV in early life. J Clin Endocrinol Metab. 2017;102(8):2896-2904. Available at https://www.ncbi.nlm.nih.gov/pubmed/28531309.